US Move to Preserve China Drug Deals Sends Biopharma Stocks Soaring

A Market Rally Rooted in Relief

Chinese biopharma stocks jumped in Hong Kong on Monday after a report that the U.S. is considering rules that would allow American pharmaceutical companies to continue licensing most drugs from Chinese firms. The news sent a jolt of optimism through a sector that has spent months bracing for the kind of sweeping restrictions that have already reshaped other industries tied to China.

Innovent Biologics jumped 6%, while Akeso surged 8% and CSPC Pharmaceutical Group gained more than 6%. HUTCHMED climbed 3%, while Sino Biopharmaceutical added 8%. The gains pushed the Hang Seng Biotech Index up by more than 5% overall. For investors who had been nervously watching Washington's posture toward China, the signal was clear: the door to pharmaceutical collaboration is likely staying open — at least for now.

A Different Path Than Tech and AI

The proposed approach would put biopharma on a different track from sectors such as artificial intelligence and semiconductors, where the U.S. has tightened restrictions on China. That distinction matters enormously. While chipmakers and AI developers have faced escalating export controls and investment bans, the pharmaceutical industry has quietly built an interdependence with China that would be extraordinarily difficult to unwind.

Almost half of U.S. deals to license drugs from overseas in 2025 were with Chinese companies, according to GlobalData, as cited by Reuters. That's not a niche relationship — it's a structural one. Pfizer, for example, announced a partnership worth up to $10.5 billion with Innovent in May, covering the research and development of 12 oncology programs. Deals of that scale don't happen in a vacuum; they reflect how deeply Western pharma has come to rely on Chinese innovation to fill its drug pipeline.

China's Licensing Boom Is Already Historic

China's out-licensing boom has continued despite geopolitical concerns. A record 81 deals worth a combined $110 billion were completed in the first half of 2026 alone, according to NMPA data cited by Nomura. To put that in perspective, cross-border licensing deals between Greater China-based biopharmaceutical companies and global drugmakers reached an unprecedented $137.7 billion across all of 2025 — a nearly tenfold increase from 2021's $13.9 billion.

Patent cliff pressures and R&D cost-cutting are driving Big Pharma to Chinese-developed drug candidates, with analysts predicting China's early-stage pipeline advantage will persist for "at least the next several years." According to Pitchbook analyst Ben Zercher, China's biotech ecosystem has "gained the lead" in generating early-stage drug candidates. Supporting that view: the number of innovative drugs submitted for human testing by Chinese developers rose from 688 in 2019 to 2,298 in 2023.

What Comes Next

Nomura noted that investors now appear "largely immune" to intermittent geopolitical concerns around the sector, citing Chinese companies' strong value proposition in novel drug development. China has also made globalization a key goal for pharmaceutical and biotech companies under its 15th five-year plan. That strategic commitment from Beijing, combined with surging Western demand, creates a powerful current that policy alone would struggle to reverse.

The critical question now is whether Washington formalizes this carve-out for biopharma or leaves the industry in a prolonged state of uncertainty. As regulatory discussions continue in Washington, market participants are closely monitoring whether finalized guidelines will codify this functional separation between biopharma and other restricted technology classes. For patients waiting on the next generation of cancer treatments and other therapies, the stakes in that policy debate extend well beyond stock prices.